S&P 500   4,226.87 (-1.33%)
DOW   33,691.86 (-0.90%)
QQQ   323.03 (-1.90%)
AAPL   171.72 (-1.40%)
MSFT   286.34 (-1.32%)
META   168.04 (-3.79%)
GOOGL   117.33 (-2.36%)
AMZN   138.36 (-2.77%)
TSLA   889.92 (-2.06%)
NVDA   179.02 (-4.64%)
NIO   19.07 (-4.22%)
BABA   89.48 (-1.39%)
AMD   96.01 (-4.41%)
T   18.37 (-0.33%)
MU   60.46 (-4.00%)
CGC   3.77 (-1.05%)
F   15.87 (-1.73%)
GE   77.85 (-1.72%)
DIS   120.27 (-1.96%)
AMC   17.66 (-8.45%)
PYPL   96.70 (-3.16%)
PFE   49.14 (+1.15%)
NFLX   239.82 (-2.18%)
S&P 500   4,226.87 (-1.33%)
DOW   33,691.86 (-0.90%)
QQQ   323.03 (-1.90%)
AAPL   171.72 (-1.40%)
MSFT   286.34 (-1.32%)
META   168.04 (-3.79%)
GOOGL   117.33 (-2.36%)
AMZN   138.36 (-2.77%)
TSLA   889.92 (-2.06%)
NVDA   179.02 (-4.64%)
NIO   19.07 (-4.22%)
BABA   89.48 (-1.39%)
AMD   96.01 (-4.41%)
T   18.37 (-0.33%)
MU   60.46 (-4.00%)
CGC   3.77 (-1.05%)
F   15.87 (-1.73%)
GE   77.85 (-1.72%)
DIS   120.27 (-1.96%)
AMC   17.66 (-8.45%)
PYPL   96.70 (-3.16%)
PFE   49.14 (+1.15%)
NFLX   239.82 (-2.18%)
S&P 500   4,226.87 (-1.33%)
DOW   33,691.86 (-0.90%)
QQQ   323.03 (-1.90%)
AAPL   171.72 (-1.40%)
MSFT   286.34 (-1.32%)
META   168.04 (-3.79%)
GOOGL   117.33 (-2.36%)
AMZN   138.36 (-2.77%)
TSLA   889.92 (-2.06%)
NVDA   179.02 (-4.64%)
NIO   19.07 (-4.22%)
BABA   89.48 (-1.39%)
AMD   96.01 (-4.41%)
T   18.37 (-0.33%)
MU   60.46 (-4.00%)
CGC   3.77 (-1.05%)
F   15.87 (-1.73%)
GE   77.85 (-1.72%)
DIS   120.27 (-1.96%)
AMC   17.66 (-8.45%)
PYPL   96.70 (-3.16%)
PFE   49.14 (+1.15%)
NFLX   239.82 (-2.18%)
S&P 500   4,226.87 (-1.33%)
DOW   33,691.86 (-0.90%)
QQQ   323.03 (-1.90%)
AAPL   171.72 (-1.40%)
MSFT   286.34 (-1.32%)
META   168.04 (-3.79%)
GOOGL   117.33 (-2.36%)
AMZN   138.36 (-2.77%)
TSLA   889.92 (-2.06%)
NVDA   179.02 (-4.64%)
NIO   19.07 (-4.22%)
BABA   89.48 (-1.39%)
AMD   96.01 (-4.41%)
T   18.37 (-0.33%)
MU   60.46 (-4.00%)
CGC   3.77 (-1.05%)
F   15.87 (-1.73%)
GE   77.85 (-1.72%)
DIS   120.27 (-1.96%)
AMC   17.66 (-8.45%)
PYPL   96.70 (-3.16%)
PFE   49.14 (+1.15%)
NFLX   239.82 (-2.18%)
NASDAQ:EXEL

Exelixis - EXEL Stock Forecast, Price & News

$19.31
+0.09 (+0.47%)
(As of 08/19/2022 03:28 PM ET)
Add
Compare
Today's Range
$19.09
$19.38
50-Day Range
$17.57
$22.27
52-Week Range
$15.50
$23.40
Volume
49,499 shs
Average Volume
2.22 million shs
Market Capitalization
$6.21 billion
P/E Ratio
22.99
Dividend Yield
N/A
Price Target
$30.56

Exelixis MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
57.9% Upside
$30.56 Price Target
Short Interest
Healthy
2.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.63
Upright™ Environmental Score
News Sentiment
0.67mentions of Exelixis in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$342,567 Sold Last Quarter
Proj. Earnings Growth
40.91%
From $0.88 to $1.24 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.35 out of 5 stars

Medical Sector

2nd out of 1,119 stocks

Biological Products, Except Diagnostic Industry

1st out of 178 stocks

EXEL stock logo

About Exelixis (NASDAQ:EXEL) Stock

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Analysts Set New Price Targets

Several analysts have commented on the stock. Piper Sandler lifted their target price on shares of Exelixis from $30.00 to $32.00 and gave the stock an "overweight" rating in a research note on Tuesday, July 26th. BMO Capital Markets began coverage on shares of Exelixis in a research note on Thursday, June 23rd. They set an "outperform" rating and a $28.00 price objective for the company. Jefferies Financial Group began coverage on shares of Exelixis in a research note on Thursday, May 12th. They set a "buy" rating and a $28.00 price objective for the company. Morgan Stanley boosted their price objective on shares of Exelixis from $22.00 to $23.00 and gave the company an "equal weight" rating in a research note on Friday, July 15th. Finally, StockNews.com cut shares of Exelixis from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, May 18th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Exelixis presently has a consensus rating of "Moderate Buy" and a consensus target price of $30.56.

Exelixis Trading Down 0.5 %

NASDAQ:EXEL opened at $19.22 on Friday. The firm has a market capitalization of $6.19 billion, a price-to-earnings ratio of 22.88, a PEG ratio of 0.60 and a beta of 0.60. The firm's fifty day simple moving average is $20.57 and its 200 day simple moving average is $20.58. Exelixis has a twelve month low of $15.50 and a twelve month high of $23.40.

Insiders Place Their Bets

In other Exelixis news, EVP Patrick J. Haley sold 18,812 shares of the business's stock in a transaction on Friday, May 27th. The shares were sold at an average price of $18.21, for a total value of $342,566.52. Following the transaction, the executive vice president now owns 239,818 shares in the company, valued at approximately $4,367,085.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.90% of the stock is currently owned by company insiders.

Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

EXEL Stock News Headlines

Exelixis (NASDAQ:EXEL) Given New $26.00 Price Target at Cowen
Exelixis (NASDAQ:EXEL) Could Easily Take On More Debt
Why did Exelixis stock slip today? - Seeking Alpha
Exelixis (EXEL) Q2 2022 Earnings Call Transcript
Here's what to expect from Exelixis's earnings report
Analysts Set Exelixis, Inc. (NASDAQ:EXEL) PT at $31.13
See More Headlines
Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

EXEL Company Calendar

Last Earnings
11/02/2021
Today
8/19/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:EXEL
CUSIP
30161Q10
Employees
954
Year Founded
1994

Price Target and Rating

Average Stock Price Forecast
$30.56
High Stock Price Forecast
$42.00
Low Stock Price Forecast
$23.00
Forecasted Upside/Downside
+58.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$231.06 million
Pretax Margin
22.19%

Debt

Sales & Book Value

Annual Sales
$1.43 billion
Cash Flow
$0.77 per share
Book Value
$7.43 per share

Miscellaneous

Free Float
312,499,000
Market Cap
$6.21 billion
Optionable
Optionable
Beta
0.60

Social Links


Key Executives

  • Dr. Stelios  Papadopoulos Ph.D.Dr. Stelios Papadopoulos Ph.D. (Age 74)
    Co-Founder & Independent Chair of the Board
    Comp: $98k
  • Dr. Michael M. Morrissey Ph.D. (Age 61)
    CEO, Pres & Director
    Comp: $2.37M
  • Mr. Christopher J. SennerMr. Christopher J. Senner (Age 54)
    Exec. VP & CFO
    Comp: $1.09M
  • Dr. Peter Lamb Ph.D. (Age 61)
    Exec. VP of Scientific Strategy & Chief Scientific Officer
    Comp: $909.46k
  • Mr. Jeffrey J. Hessekiel J.D.Mr. Jeffrey J. Hessekiel J.D. (Age 53)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $957.2k
  • Mr. Patrick J. Haley M.B.A.Mr. Patrick J. Haley M.B.A. (Age 46)
    MBA, Exec. VP of Commercial
    Comp: $846.43k
  • Dr. Dana T. Aftab Ph.D.
    Exec. VP of Bus. Operations
  • Ms. Susan T. Hubbard
    Exec. VP of Public Affairs & Investor Relations
  • Mr. Gregg Bernier
    VP of Marketing
  • Ms. Laura Dillard
    Exec. VP of HR













EXEL Stock - Frequently Asked Questions

Should I buy or sell Exelixis stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EXEL shares.
View EXEL analyst ratings
or view top-rated stocks.

What is Exelixis' stock price forecast for 2022?

8 analysts have issued 1 year price targets for Exelixis' stock. Their EXEL share price forecasts range from $23.00 to $42.00. On average, they predict the company's stock price to reach $30.56 in the next twelve months. This suggests a possible upside of 59.0% from the stock's current price.
View analysts price targets for EXEL
or view top-rated stocks among Wall Street analysts.

How have EXEL shares performed in 2022?

Exelixis' stock was trading at $18.28 at the beginning of 2022. Since then, EXEL stock has increased by 5.1% and is now trading at $19.22.
View the best growth stocks for 2022 here
.

When is Exelixis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our EXEL earnings forecast
.

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) announced its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.19 by $0.07. The biotechnology company earned $328.42 million during the quarter, compared to the consensus estimate of $366.34 million. Exelixis had a net margin of 17.53% and a trailing twelve-month return on equity of 12.10%. During the same quarter in the prior year, the company posted ($0.10) earnings per share.

What guidance has Exelixis issued on next quarter's earnings?

Exelixis issued an update on its FY 2022 earnings guidance on Tuesday, August, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.52 billion-$1.63 billion, compared to the consensus revenue estimate of $1.59 billion.

What is Michael M. Morrissey's approval rating as Exelixis' CEO?

32 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among the company's employees.

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Who are Exelixis' major shareholders?

Exelixis' stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (5.54%), FMR LLC (5.41%), Price T Rowe Associates Inc. MD (4.17%), State Street Corp (3.91%), Meditor Group Ltd (2.41%) and Goldman Sachs Group Inc. (1.36%). Insiders that own company stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, Gisela Schwab, Jack L Wyszomierski, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi.
View institutional ownership trends
.

How do I buy shares of Exelixis?

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $19.22.

How much money does Exelixis make?

Exelixis (NASDAQ:EXEL) has a market capitalization of $6.19 billion and generates $1.43 billion in revenue each year. The biotechnology company earns $231.06 million in net income (profit) each year or $0.84 on an earnings per share basis.

How many employees does Exelixis have?

The company employs 954 workers across the globe.

When was Exelixis founded?

Exelixis was founded in 1994.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The official website for the company is www.exelixis.com. The biotechnology company can be reached via phone at (650) 837-7000, via email at shubbard@exelixis.com, or via fax at 650-837-8300.

This page (NASDAQ:EXEL) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.